Blueprint Medicines Corporation

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Blueprint Medicines Corporation sits in the top decile of US sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count).

24 total trials 6 currently recruiting 12 completed early-phase tilt top decile by trial count

Blueprint Medicines Corporation: 24 sponsored US clinical trials, 6 recruiting.

Blueprint Medicines Corporation sponsors 24 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 12 completed. 1 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is KIT D816V Mutation, with 2 trials.

Top-decile sponsor footprint

Blueprint Medicines Corporation ranks in the top decile of sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 16/100

12 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

24 total, page 1 of 1

RECRUITING Phase 1

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

NCT07629960
RECRUITING

An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

NCT07264959
RECRUITING Phase 1

A Study of Elenestinib in Healthy Adult Female Participants

NCT07388511
RECRUITING

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

NCT07143669
RECRUITING Phase 2

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

NCT06931405
RECRUITING Phase 2

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT04910685
ACTIVE NOT RECRUITING Phase 2

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT03731260
COMPLETED Phase 1

Study of BLU-808 in Healthy Adult Participants

NCT06948032
TERMINATED Phase 1

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

NCT05609942
COMPLETED Phase 1

A Drug-drug Interaction Study of Avapritinib and Midazolam

NCT04908176
TERMINATED Phase 1

(VELA) Study of BLU-222 in Advanced Solid Tumors

NCT05252416
TERMINATED Phase 1

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

NCT05241873
COMPLETED Phase 1

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

NCT04773782
TERMINATED Phase 1

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

NCT05153408
COMPLETED

(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation

NCT04811365
TERMINATED Phase 1

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

NCT04862780
COMPLETED

Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

NCT04695431
COMPLETED Phase 1

Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults

NCT03858075
COMPLETED Phase 2

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

NCT03580655
COMPLETED Phase 3

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

NCT03465722
COMPLETED Phase 1

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

NCT02561988
COMPLETED

Mast Cell Connect: A Registry for Patients With Mastocytosis

NCT02620254
COMPLETED Phase 1

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

NCT02508532
COMPLETED Phase 1

A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

NCT02508467

Phase Distribution

PhaseTrial count
Phase 1 14
Phase 2 4
Phase 3 1

Therapeutic Areas

KIT D816V Mutation 2
Indolent Systemic Mastocytosis 2
Healthy Participants 2
Systemic Mast Cell Activation 1
Mast Cell Leukemia 1
Aggressive Systemic Mastocytosis 1
Advanced Systemic Mastocytosis 1
GIST 1
Smoldering Systemic Mastocytosis 1
Systemic Mastocytosis With an Associated Hematologic Neoplasm 1

What is open in the Blueprint Medicines Corporation pipeline

6 recruiting of 24 indexed (25% open); 12 completed (50%).

Phase mix: 1 late (III/IV) vs 18 early (I/II) (early-phase heavy).

Top condition: KIT D816V Mutation (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Blueprint Medicines Corporation: open-pipeline peers nationwide

Peers matched on 24 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

Blueprint Medicines Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%10%20%30% Total trials Recruiting share Blueprint Medicines CorporationAcrotech BiopharmaAgenusAkebia TherapeuticsConcert PharmaceuticalsAB ScienceAbbott Point of CareAbdul Latif Jameel Poverty Action LabAccutar Biotechnology
Blueprint Medicines Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Blueprint Medicines Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 24 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Blueprint Medicines Corporation page

24 registered trials is a research-attention snapshot, not an endorsement of Blueprint Medicines Corporation or any single study.

  • 6 of Blueprint Medicines Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • KIT D816V Mutation is the condition Blueprint Medicines Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See KIT D816V Mutation trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Blueprint Medicines Corporation pipeline card: 24 registered trials from official public datasets.Report a data error.